Finder makes money from featured partners, but editorial opinions are our own. Advertiser disclosure

How to buy ATAI Life Sciences stock (Atai Life Sciences)

Buy ATAI Life Sciences stock in 5 easy steps, view past price performance and learn what’s ahead for the company.

Atai Life Sciences, a Peter Thiel-backed company that produces psychedelic and non-psychedelic mushroom-based therapies for depression and anxiety, is expected to go public. We'll update this page as new information emerges.

Our top picks for where to buy ATAI Life Sciences BV stock

Top pick for advanced traders

Go to site
  • Trade options, futures, options on futures, stocks, ETFs
  • $0 commission to close options
  • Pro-grade platform and risk analysis tools

Our pick for investing by theme

Go to site
  • Trade $0 commission stocks & ETFs with as little as $1
  • Theme and ETF screener
  • Discover new opportunities with Opto's AI-driven classification system

Our pick for transfer bonus

Go to site
  • Trade stocks, options, ETFs, mutual funds, alternative asset funds
  • $0 commission on stocks, ETFs and options, with no options contract fees
  • Complimentary access to a financial planner and automated investing

How to buy ATAI Life Sciences stock

  1. Choose a stock trading platform. Use our comparison table
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – ATAI. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy ATAI Life Sciences stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.
1 - 4 of 4
Name Product USFST Ratings Available asset types Stock trade fee Minimum deposit Cash sweep APY Signup bonus
Tastytrade
Finder Score: 4.4 / 5: ★★★★★
Tastytrade
★★★★★
Stocks, Options, ETFs, Cryptocurrency, Futures, Treasury Bills
$0
$0
N/A
Get $50-$5,000
Competitive, capped options commissions, with a reliable trading platform designed for serious traders.
OPTO
Finder Score: 3.1 / 5: ★★★★★
OPTO
★★★★★
Stocks, ETFs
$0
$0
N/A
Earn up to $300
AI-driven thematic investing, with proprietary research, fractional shares and commission-free stocks and ETFs.
SoFi Invest®
Finder Score: 4.2 / 5: ★★★★★
SoFi Invest®
★★★★★
Stocks, Options, Mutual funds, ETFs, Alternatives
$0
$0
0.02%
Get up to $1,000 in stock
Zero-commission stocks, ETFs and options, with no options per-contract fees. Plus, a no-advisory-fee robo-advisor and complimentary access to financial planners.
Robinhood
Finder Score: 4.5 / 5: ★★★★★
Robinhood
★★★★★
Stocks, Options, ETFs, Cryptocurrency
$0
$0
4.5%
Get a free stock
Trade stocks, options, ETFs and crypto without commissions and on a user-friendly platform. Plus, a 1% IRA match and no options contract fees.
loading

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

ATAI Life Sciences stock price (NASDAQ: ATAI)

Use our graph to track the performance of ATAI stocks over time.

ATAI Life Sciences shares at a glance

Information last updated 2024-10-25.
Latest market close$1.14
52-week range$1.03 - $2.85
50-day moving average $1.21
200-day moving average $1.60
Wall St. target price$11.60
PE ratio N/A
Dividend yield N/A
Earnings per share (TTM) $-0.36

Is it a good time to buy ATAI Life Sciences stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ATAI Life Sciences price performance over time

Historical closes compared with the close of $1.22 from 2024-10-28

1 week (2024-10-22) -4.69%
1 month (2024-09-30) 5.17%
3 months (2024-07-30) -19.74%
6 months (2024-04-30) -38.38%
1 year (2023-10-30) 2.52%
2 years (2022-10-27) -59.20%
3 years (2021-10-29) 14.59
5 years (2019-10-26) N/A

ATAI Life Sciences financials

Revenue TTM $378,000
Gross profit TTM $233,000
Return on assets TTM -27.97%
Return on equity TTM -31.51%
Profit margin 0%
Book value $1.00
Market Capitalization $203 million

TTM: trailing 12 months

ATAI Life Sciences share dividends

We're not expecting ATAI Life Sciences to pay a dividend over the next 12 months.

You may also wish to consider:

ATAI Life Sciences share price volatility

Over the last 12 months, ATAI Life Sciences's shares have ranged in value from as little as $1.025 up to $2.85. A popular way to gauge a stock's volatility is its "beta".

ATAI.US volatility(beta: 0.78)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ATAI Life Sciences's is 0.781. This would suggest that ATAI Life Sciences's shares are less volatile than average (for this exchange).

To put ATAI Life Sciences's beta into context you can compare it against those of similar companies.

ATAI Life Sciences overview

Atai Life Sciences N. V. , a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression.

Frequently asked questions

null
What percentage of ATAI Life Sciences is owned by insiders or institutions?
Currently 9.987% of ATAI Life Sciences shares are held by insiders and 27.098% by institutions.
How many people work for ATAI Life Sciences?
Latest data suggests 83 work at ATAI Life Sciences.
When does the fiscal year end for ATAI Life Sciences?
ATAI Life Sciences's fiscal year ends in December.
Where is ATAI Life Sciences based?
ATAI Life Sciences's address is: Wallstrasse 16, Berlin, Germany, 10179
What is ATAI Life Sciences's ISIN number?
ATAI Life Sciences's international securities identification number is: NL0015000DX5

More guides on Finder

Ask a question

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Go to site